| Date | Time | Source | Announcement |
|---|---|---|---|
| 06 Dec 2004 | 07:00 AM | New Cancer Collaboration | |
| 03 Dec 2004 | 04:14 PM | Shareholding | |
| 01 Dec 2004 | 07:00 AM | Drug Discovery Collaboration | |
| 29 Nov 2004 | 02:13 PM | Holding(s) in Company | |
| 22 Nov 2004 | 07:00 AM | Collaboration Agreement | |
| 15 Nov 2004 | 11:56 AM | Holding(s) in Company | |
| 09 Nov 2004 | 07:00 AM | Collaborative Agreement | |
| 26 Oct 2004 | 05:29 PM | Holding(s) in Company | |
| 11 Oct 2004 | 07:00 AM | First day of dealings on AIM |
Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.
The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.
SAR share price listed on AIM in 2004 under the ticker SAR.